Werewolf Therapeutics (HOWL) Net Cash Flow (2020 - 2026)
Werewolf Therapeutics (HOWL) posted quarterly Net Cash Flow of $6.6 million for Q2 2026, up 144.86% year-over-year from $2.7 million in Q2 2025, and up 162.56% on a QoQ basis from -$10.6 million in Q1 2026.
Werewolf Therapeutics (HOWL) Net Cash Flow (2020 - 2026) Analysis & Trends
Werewolf Therapeutics has reported Net Cash Flow for 7 years, with the latest figure at $6.6 million in Q2 2026.
- Net Cash Flow for Q2 2026 came in at $6.6 million, up 144.86% year-over-year; the trailing twelve-month figure through Jun 2026 was -$24.5 million (up 57.76% YoY), and the FY2025 annual result was -$54.3 million, down 25.14% from the prior year.
- Net Cash Flow climbed to $6.6 million in Q2 2026, from -$10.6 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $38.6 million in Q1 2023 and troughed at -$23.9 million in Q2 2024.
- A 5-year average of -$5.8 million and a median of -$10.5 million in 2023 frame the typical range for Net Cash Flow.
- The largest YoY upside for Net Cash Flow was 378.99% in 2023 against a maximum downside of 620.29% in 2023.
- A 5-year view of Net Cash Flow shows it stood at -$11.1 million in 2022, then soared by 138.54% to $4.3 million in 2023, then slumped by 375.71% to -$11.8 million in 2024, then gained by 26.8% to -$8.7 million in 2025, then surged by 176.57% to $6.6 million in 2026.
- Per Business Quant data, the three most recent Net Cash Flow figures were $6.6 million in Q2 2026, -$10.6 million in Q1 2026, and -$8.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Werewolf Therapeutics | 43.94 Mn | 43.94 Mn | - | 6.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.63 Mn |
| Jun 30, 2026 | 6.63 Mn |
| Mar 31, 2026 | -10.60 Mn |
| Mar 31, 2026 | -10.60 Mn |
| Dec 31, 2025 | -8.66 Mn |
| Dec 31, 2025 | -8.66 Mn |
| Sep 30, 2025 | -11.88 Mn |
| Sep 30, 2025 | -11.88 Mn |
| Jun 30, 2025 | -14.78 Mn |
| Jun 30, 2025 | -14.78 Mn |
| Mar 31, 2025 | -18.95 Mn |
| Mar 31, 2025 | -18.95 Mn |
| Dec 31, 2024 | -11.83 Mn |
| Dec 31, 2024 | -11.83 Mn |
| Sep 30, 2024 | -12.47 Mn |
| Sep 30, 2024 | -12.47 Mn |
| Jun 30, 2024 | -23.91 Mn |
| Jun 30, 2024 | -23.91 Mn |
| Mar 31, 2024 | 4.85 Mn |
| Mar 31, 2024 | 4.85 Mn |